Method and system for treatment of cardiovascular disorders
First Claim
Patent Images
1. A method of treating a cardiovascular disorder in a subject, comprising:
- providing an extracellular matrix (ECM) composition comprising acellular bioremodelable mesothelial tissue, said mesothelial tissue comprising endogenous proteoglycans, transforming growth factor-β
(TGF-β
) and vascular endothelial growth factor (VEGF) that collectively induce myofibroblast and stem cell migration, and differentiation of said stem cells into cardiomyocytes when administered to damaged cardiovascular tissue;
providing a mechanical circulatory support (MSC) device that is configured to support ventricular function of a mammalian heart when connected thereto;
connecting said MSC device to said subject'"'"'s circulatory system;
administering said ECM composition proximate damaged cardiovascular tissue of said subject'"'"'s heart, wherein said ECM composition induces neovascularization and bioremodeling of said subject'"'"'s damaged cardiovascular tissue; and
providing support of ventricular function of said subject'"'"'s heart with said MSC device.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods for treating a cardiovascular disorder comprising administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance.
-
Citations
2 Claims
-
1. A method of treating a cardiovascular disorder in a subject, comprising:
-
providing an extracellular matrix (ECM) composition comprising acellular bioremodelable mesothelial tissue, said mesothelial tissue comprising endogenous proteoglycans, transforming growth factor-β
(TGF-β
) and vascular endothelial growth factor (VEGF) that collectively induce myofibroblast and stem cell migration, and differentiation of said stem cells into cardiomyocytes when administered to damaged cardiovascular tissue;providing a mechanical circulatory support (MSC) device that is configured to support ventricular function of a mammalian heart when connected thereto; connecting said MSC device to said subject'"'"'s circulatory system; administering said ECM composition proximate damaged cardiovascular tissue of said subject'"'"'s heart, wherein said ECM composition induces neovascularization and bioremodeling of said subject'"'"'s damaged cardiovascular tissue; and providing support of ventricular function of said subject'"'"'s heart with said MSC device. - View Dependent Claims (2)
-
Specification